Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 16/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 16/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 13/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 13/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 13/20 | 0.71 |
| ▸ | HDAC5 | Q9UQL6 | 10/20 | 0.71 |
| ▸ | HDAC4 | P56524 | 7/20 | 0.63 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.63 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.50 |
| ▸ | KDM1A | O60341 | 2/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2404317 | 1.00 | HDAC1 (1.00) | HDAC1HDAC3HDAC6HDAC2HDAC8 | |
| SCHEMBL22332695 | 0.94 | HDAC1 (0.89) | HDAC1HDAC3HDAC6HDAC2HDAC8 | |
| SCHEMBL2403201 | 0.89 | HDAC1 (0.79) | HDAC1HDAC3HDAC6HDAC2HDAC8 | |
| SCHEMBL2403208 | 0.89 | HDAC1 (0.79) | HDAC1HDAC3HDAC6HDAC2HDAC8 | |
| SCHEMBL2404198 | 0.88 | HDAC1 (0.78) | HDAC1HDAC3HDAC6HDAC2HDAC8 | |
| SCHEMBL2404193 | 0.88 | HDAC1 (0.78) | HDAC1HDAC3HDAC6HDAC2HDAC8 | |
| SCHEMBL2402840 | 0.87 | HDAC1 (0.77) | HDAC1HDAC3HDAC6HDAC2HDAC8 | |
| SCHEMBL2402836 | 0.87 | HDAC1 (0.77) | HDAC1HDAC3HDAC6HDAC2HDAC8 | |
| SCHEMBL16653762 | 0.85 | HDAC6 (0.74) | HDAC1HDAC3HDAC6HDAC2HDAC8 | |
| SCHEMBL16653760 | 0.85 | HDAC6 (0.74) | HDAC1HDAC3HDAC6HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212943-A1 | NOVEL BRIDGED CYCLIC COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2011-09-01 | — | — | US | claimed |
| WO-2010043953-A2 | NOVEL BRIDGED CYCLIC COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | ORCHID RESEARCH LABORATORIES LTD. (IN) | 2010-04-22 | — | — | WO | claimed |
| US-12491270-B2 | Imaging histone deacetylases with a radiotracer using positron emission tomography | THE GENERAL HOSPITAL CORPORATION (US) | 2025-12-09 | — | — | US | disclosed |
| US-20210030899-A1 | IMAGING HISTONE DEACETYLASES WITH A RADIOTRACER USING POSITRON EMISSION TOMOGRAPHY | THE GENERAL HOSPITAL CORPORATION | 2021-02-04 | — | — | US | disclosed |
| EP-3769757-A2 | IMAGING HISTONE DEACETYLASES WITH A RADIOTRACER USING POSITRON EMISSION TOMOGRAPHY | The General Hospital Corporation (US) | 2021-01-27 | — | — | EP | disclosed |
| US-10842891-B2 | Imaging histone deacetylases with a radiotracer using positron emission tomography | THE GENERAL HOSPITAL CORPORATION (US) | 2020-11-24 | — | — | US | disclosed |
| EP-3062783-B1 | IMAGING HISTONE DEACETYLASES WITH A RADIOTRACER USING POSITRON EMISSION TOMOGRAPHY | MASSACHUSETTS GEN HOSPITAL (US) | 2020-08-12 | — | — | EP | disclosed |
| US-20190240357-A1 | IMAGING HISTONE DEACETYLASES WITH A RADIOTRACER USING POSITRON EMISSION TOMOGRAPHY | THE GENERAL HOSPITAL CORPORATION | 2019-08-08 | — | — | US | disclosed |
| US-10188756-B2 | Imaging histone deacetylases with a radiotracer using positron emission tomography | THE GENERAL HOSPITAL CORPORATION (US) | 2019-01-29 | — | — | US | disclosed |
| US-20160271276-A1 | IMAGING HISTONE DEACETYLASES WITH A RADIOTRACER USING POSITRON EMISSION TOMOGRAPHY | THE GENERAL HOSPITAL CORPORATION | 2016-09-22 | — | — | US | disclosed |
| US-20110212943-A1 | NOVEL BRIDGED CYCLIC COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190240357-A1 | IMAGING HISTONE DEACETYLASES WITH A RADIOTRACER USING POSITRON EMISSION TOMOGRAPHY | HDAC1, HDAC11, HDAC3 | HDAC1 1/4885HDAC3 3/4885HDAC6 13/4885 |
| US-10188756-B2 | Imaging histone deacetylases with a radiotracer using positron emission tomography | HDAC1, HDAC11, HDAC3 | HDAC1 1/4885HDAC3 3/4885HDAC6 13/4885 |
| US-20210030899-A1 | IMAGING HISTONE DEACETYLASES WITH A RADIOTRACER USING POSITRON EMISSION TOMOGRAPHY | HDAC1, HDAC11, HDAC3 | HDAC1 1/4885HDAC3 3/4885HDAC6 13/4885 |
| US-20160271276-A1 | IMAGING HISTONE DEACETYLASES WITH A RADIOTRACER USING POSITRON EMISSION TOMOGRAPHY | HDAC1, HDAC11, HDAC3 | HDAC1 1/4885HDAC3 3/4885HDAC6 13/4885 |
| US-12491270-B2 | Imaging histone deacetylases with a radiotracer using positron emission tomography | HDAC1, HDAC11, HDAC3 | HDAC1 1/4885HDAC3 3/4885HDAC6 13/4885 |
| US-20110212943-A1 | NOVEL BRIDGED CYCLIC COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC7 | HDAC1 1/4885HDAC3 10/4885HDAC6 8/4885 |
| US-10842891-B2 | Imaging histone deacetylases with a radiotracer using positron emission tomography | HDAC1, HDAC11, HDAC3 | HDAC1 1/4885HDAC3 3/4885HDAC6 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.